Tg Therapeutics: Bollinger Bands Narrowing, KDJ Death Cross on 15min Chart

Tg Therapeutics's 15-minute chart has recently exhibited Bollinger Bands Narrowing, and a KDJ Death Cross is projected to occur on September 18, 2025, at 12:00. This signals a reduction in the magnitude of stock price fluctuations and a shift in momentum towards the downside, with the potential for further decreases in stock price.

TG Therapeutics (TGTX) has recently experienced a notable shift in its stock price dynamics, with technical indicators suggesting a potential downturn. Analysts, however, remain optimistic about the company's future prospects.

On September 12, 2025, a 15-minute chart analysis of TGTX revealed a narrowing of Bollinger Bands, indicating a reduction in the magnitude of stock price fluctuations. Additionally, a KDJ Death Cross is projected to occur on September 18, 2025, at 12:00, which signals a shift in momentum towards the downside, potentially leading to further decreases in stock price TGTX: B. Riley Securities Raises Price Target on TG Therapeutics | TGTX Stock News^[1].

Despite these technical signals, analysts at B. Riley Securities maintain a Buy rating for TGTX, raising the price target from $53.00 to $55.00, reflecting a 3.77% increase. The analyst responsible for this update, Mayank Mamtani, attributes the increase to recent market evaluations and strategic company developments TGTX: B. Riley Securities Raises Price Target on TG Therapeutics | TGTX Stock News^[1].

The consensus among Wall Street analysts is also favorable, with an average target price of $42.00 and an average brokerage recommendation of "Outperform". GuruFocus estimates a GF Value for TGTX of $89.71, suggesting a potential upside of 177.48% from the current price of $32.33 TGTX: B. Riley Securities Raises Price Target on TG Therapeutics | TGTX Stock News^[1].

However, the projected KDJ Death Cross and Bollinger Bands narrowing indicate a cautious approach for investors. While the company's pipeline and recent FDA approval for BRIUMVI for the treatment of relapsing forms of multiple sclerosis (RMS) are positive developments, the technical indicators suggest a potential downward trend in the short term.

Investors should closely monitor TGTX's stock performance and consider the implications of the upcoming KDJ Death Cross on September 18, 2025, while also keeping an eye on the company's broader strategic developments and market evaluations.